stockportfolio.pro
Esperion Therapeutics, Inc. (ESPR)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGM
Esperion Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $148.36M | $227.55M | $78.45M | $75.47M | $116.33M | $332.31M | $403.13M |
| Gross profit | — | — | — | — | — | — | $48.51M | $73.07M | $263.71M | $273.91M |
| Net income | $-74.98M | $-166.99M | $-201.81M | $-97.17M | $-143.55M | $-269.11M | $-233.66M | $-209.25M | $-51.74M | $-22.68M |
| Net margin | — | — | — | -65.5% | -63.1% | -343.0% | -309.6% | -179.9% | -15.6% | -5.6% |
Source: Esperion Therapeutics, Inc. SEC filings (10-K). 15 years of history available in the interactive view.
Explore 15 years of Esperion Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ESPR in your portfolio →
Esperion Therapeutics, Inc. financial history by metric
About Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics, Inc. — frequently asked questions
What is Esperion Therapeutics, Inc.'s revenue?
Esperion Therapeutics, Inc. (ESPR) reported revenue of $403.13M for fiscal year 2025, up 21.3% from the prior year, according to its SEC filings.
Is Esperion Therapeutics, Inc. profitable?
No — ESPR reported a net loss of $-22.68M in fiscal 2025.
What is ESPR's P/E ratio?
Esperion Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Esperion Therapeutics, Inc. growing?
ESPR's revenue grew at roughly 12.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Esperion Therapeutics, Inc. have?
As of fiscal year 2025, ESPR carried roughly $249.48M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Esperion Therapeutics, Inc.'s gross margin?
ESPR's gross margin was 67.9% in fiscal 2025 — gross profit of $273.91M on revenue of $403.13M.
What is Esperion Therapeutics, Inc.'s market cap?
Esperion Therapeutics, Inc. (ESPR) has a market capitalization of about $810.45M, based on the latest data in our nightly-refreshed cache.
When does Esperion Therapeutics, Inc.'s fiscal year end?
ESPR's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Esperion Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 15 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.